Drugs /
tipapkinogene sovacivec
Overview
Clinical Trials
Tipapkinogene sovacivec has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating tipapkinogene sovacivec, 1 is phase 1/phase 2 (1 open).
CDKN2A Overexpression and HPV Positive are the most frequent biomarker inclusion criteria for tipapkinogene sovacivec clinical trials.
Anal squamous cell carcinoma, cervical squamous cell carcinoma, and penile carcinoma are the most common diseases being investigated in tipapkinogene sovacivec clinical trials [2].
References
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].
2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.